-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2022-501876-24-00
3
2022-06-17
Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-524542-10-00
4
2026-04-14
Endometrial cancer
-
2025-521012-18-00
5
2026-04-13
Facioscapulohumeral Muscular Dystrophy (FSHD)
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2025-522338-30-00
4
2026-03-31
Ulcerative Colitis
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2025-522613-26-00
7
2026-03-13
Advanced Solid Cancers
-
2025-521642-14-00
4
2026-03-05
Multiple System Atrophy
-
2025-522120-28-00
4
2026-03-03
Locally Advanced Rectal Cancer (LARC) stage II (T3-4N0M0) or stage III
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2024-511101-28-00
4
2026-02-24
Episodic Migraine
Chronic Migraine
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.